Perf-A-Tape Cement

Product Description

Perf-A-Tape Cement was a specialty finishing compound manufactured by United States Gypsum Company (USG), one of the dominant forces in the American construction materials industry throughout the twentieth century. The product was designed for use in conjunction with perforated joint tape systems, serving as an adhesive and finishing cement that bonded tape to drywall seams and gypsum board joints. This type of compound was integral to the finishing stages of interior construction, providing the smooth, seamless surfaces required before painting or other final treatments.

USG was among the most prolific manufacturers of gypsum-based building products in the United States, supplying materials to commercial, industrial, and residential construction markets across multiple decades. Perf-A-Tape Cement occupied a specific niche within the company’s broader lineup of joint treatment products, intended for professional tradespeople who required reliable adhesion and workability during the taping and finishing process.

Although precise production dates for Perf-A-Tape Cement are not independently confirmed in all public records, USG’s broader range of joint compounds and finishing cements were widely distributed from the mid-twentieth century onward, during a period when asbestos was commonly incorporated into construction materials for its binding, fire-resistant, and tensile-strengthening properties.

Asbestos Content

Litigation records document allegations that Perf-A-Tape Cement contained asbestos as a component of its formulation. Plaintiffs alleged that asbestos fibers — most commonly chrysotile — were added to joint compounds and finishing cements of this type to improve product performance characteristics, including workability, crack resistance, and adhesion strength.

The use of asbestos in joint compounds and related finishing materials was an industry-wide practice during much of the twentieth century. Manufacturers including USG sourced chrysotile and, in some cases, other asbestos fiber types from domestic and international suppliers for incorporation into gypsum-based products. Plaintiffs alleged that Perf-A-Tape Cement was among the USG products that contained these fibers during at least a portion of its production run.

It is well established through regulatory history that asbestos-containing joint compounds were used extensively in American construction until the U.S. Consumer Product Safety Commission (CPSC) acted in the 1970s to restrict asbestos in patching compounds and related materials. USG, as a major industry participant, produced products across this regulatory timeline, and litigation records have identified various USG finishing compounds as having contained asbestos prior to reformulation or product discontinuation.

How Workers Were Exposed

Industrial workers and construction tradespeople represent the population most commonly associated with exposure to Perf-A-Tape Cement and similar asbestos-containing finishing compounds. The nature of joint compound application inherently created conditions under which asbestos fibers could become airborne and be inhaled by workers in the vicinity.

The primary exposure pathway identified in litigation records involves the mixing, application, sanding, and cleanup of joint compound materials. Dry joint cement products, when mixed with water, can release settled fibers into the air. More significantly, the sanding and abrading of dried compound — a routine and necessary step in achieving a smooth wall finish — generates fine dust that litigation records document as potentially containing respirable asbestos fibers.

Plaintiffs alleged that workers who regularly sanded dried Perf-A-Tape Cement in enclosed or poorly ventilated spaces faced repeated and prolonged inhalation exposure to asbestos-containing dust. Industrial workers employed in construction, renovation, and demolition contexts were particularly at risk, as these settings often involved sustained periods of sanding activity with minimal respiratory protection, especially in the decades before modern occupational health standards were established.

Beyond the primary applicators, bystander exposure was also documented in litigation. Other tradespeople working in the same areas — electricians, plumbers, painters, and general laborers — could be exposed to airborne asbestos dust generated by finishing work occurring nearby. In industrial facilities undergoing renovation or construction, this bystander exposure was often cumulative over the course of a worker’s career.

OSHA’s permissible exposure limits for asbestos, established and progressively tightened from the 1970s onward, reflect the recognized hazard of airborne asbestos in occupational settings. For much of the period during which Perf-A-Tape Cement was in use, no enforceable standards governed asbestos exposure in construction trades, and respiratory protection was rarely mandated or provided.

Diseases associated with occupational asbestos exposure from products such as Perf-A-Tape Cement include mesothelioma, asbestosis, lung cancer, and other asbestos-related conditions. These diseases typically have long latency periods — often twenty to fifty years between initial exposure and diagnosis — meaning that workers exposed during the mid-twentieth century may only now be receiving diagnoses.

Perf-A-Tape Cement is classified as a Tier 2 product for legal purposes, meaning that claims involving this product are pursued through active civil litigation rather than through an established asbestos bankruptcy trust fund. United States Gypsum Company has not reorganized under asbestos-related bankruptcy proceedings in the same manner as some other manufacturers, and no dedicated USG asbestos trust fund has been established specifically for this category of claimants. As a result, individuals harmed by exposure to Perf-A-Tape Cement must pursue compensation through direct litigation against available defendants.

Litigation records document that USG and related entities have been named as defendants in asbestos personal injury lawsuits filed across numerous jurisdictions in the United States. Plaintiffs alleged that USG knew or should have known about the hazards of asbestos in its products and failed to adequately warn workers and end users of those risks.

Individuals who believe they were exposed to Perf-A-Tape Cement and have received an asbestos-related diagnosis should consult with an attorney experienced in asbestos litigation. Key documentation that may support a claim includes employment records, union membership records, work site histories, co-worker testimony, product identification records, and medical records establishing a qualifying diagnosis.

Because multiple defendants are often named in asbestos litigation — including raw fiber suppliers, other product manufacturers, and premises owners — claimants may have access to compensation from several sources simultaneously. Some defendants in related litigation have established bankruptcy trusts, and exposure to Perf-A-Tape Cement on a job site may have occurred alongside exposure to other asbestos-containing products, broadening the scope of potential recovery.

Statutes of limitations govern asbestos claims and vary by state. In most jurisdictions, the limitations period begins at the time of diagnosis rather than the time of exposure, but prompt legal consultation is strongly recommended to preserve all available options.

This article is provided for informational purposes based on litigation records and publicly available regulatory history. It does not constitute legal advice. Individuals seeking compensation for asbestos-related illness should consult a qualified attorney.